HPV leaves its mark in oropharyngeal squamous cell carcinomas
Oropharyngeal squamous cell carcinoma (OPSCC) is a form of cancer that affects the cells lining the middle part of the throat, including the soft palate, the base of the tongue, the tonsils, and the pharynx. High-risk types of human papilloma virus (HPV) are increasingly detected in patients with OPSCC; however, HPV-positive OPSCC is highly curable and patients with HPV have better survival compared to HPV-negative patients, whose cancers are usually associate with alcohol and tobacco use. To understand the molecular mechanisms underlying these differences, Jochen Hess and colleagues at University Hospital Heidelberg in Heidelberg, Germany monitored changes in DNA modifications in HPV-positive and HPV-negative OPSCCs. In this issue of the Journal of Clinical Investigation, they identified a specific pattern of DNA modifications that is dependent on the presence of HPV. This DNA modification pattern was significantly correlated with improved survival in three separate groups of OPSCC patients. This study identifies a specific cellular alteration that can predict clinical outcomes for patients with OPSCC.
TITLE:
HPV-related methylation signature predicts survival in oropharyngeal squamous cell carcinomas
AUTHOR CONTACT:
Jochen Hess
University Hospital Heidelberg, Heidelberg, DEU
Phone: +49 (0)6221 56 39505; E-mail: jochen.hess@med.uni-heidelberg.de
View this article at: http://www.jci.org/articles/view/67010?key=e49a18f8713a54db36d3
Searching for therapeutic synergy in primary effusion lymphoma
Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with HIV and the elderly. Because current treatment options are not effective, there is a great need for new PEL therapies. In this issue of the Journal of Clinical Investigation, Juan Carlos Ramos and colleagues at the University of Miami used an immunocompromised mouse model of PEL to determine the efficacy of Bortezomib/Vorinostat combination therapy, two drugs that are currently being used to treat multiple myeloma and cutaneous T cell lymphoma, respectively. They found that this treatment combination reactivated virus-induced cell lysis and induced PEL cell death, increasing the lifespan of mice with PEL tumors. These findings indicate that this drug combination could potentially be beneficial in immunocompromised patients with KSHV-associated malignancies.
TITLE:
Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma
AUTHOR CONTACT:
Juan Carlos Ramos
Leonard M. Miller School of Medicine, University of Miami, Miamia, FL, USA
Phone: 305-243-6611; Fax: 305-243-5239; E-mail: jramos2@med.miami.edu
View this article at: http://www.jci.org/articles/view/64503?key=911b173313cf3a75e17c
ALSO IN THIS ISSUE
TITLE:
Plasmacytoid dendritic cells promote rotavirus-induced human and murine B-cell responses
AUTHOR CONTACT:
Harry B Greenberg
Stanford University School of Medicine, Stanford, CA, USA
Phone: 650 725 9722; E-mail: harry.greenberg@stanford.edu
View this article at: http://www.jci.org/articles/view/60945?key=92da3ab7cb1e7d28deb4
TITLE:
Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth
AUTHOR CONTACT:
Pilar Sánchez-Gómez
Instituto de Salud Carlos III-UFIEC, Majadahonda, UNK, ESP
Phone: 34918223265; Fax: 34918223269; E-mail: psanchezg@isciii.es
View this article at: http://www.jci.org/articles/view/63623?key=a0b7cd2c477b6bade3de
TITLE:
PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice
AUTHOR CONTACT:
Zhiwei Chen
AIDS Institute, Hong Kong, HKG
Phone: 85228199831; Fax: 85228199824; E-mail: zchenai@hku.hk
View this article at: http://www.jci.org/articles/view/64704?key=17828494be1b33866ebd
TITLE:
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
AUTHOR CONTACT:
So Young Kim
Duke University, Durham, NC, USA
Phone: 919-684-7955; E-mail: soyoung.kim@duke.edu
View this article at: http://www.jci.org/articles/view/66343?key=13fcaece6930940c5e5a
TITLE:
Fetal-derived adrenomedullin mediates the innate immune milieu of the placenta
AUTHOR CONTACT:
Kathleen M. Caron
The Univ. of North Carolina-Chapel Hill, Chapel Hill, NC, USA
Phone: (919) 966-5215; Fax: (919) 966-5230; E-mail: kathleen_caron@med.unc.edu
View this article at: http://www.jci.org/articles/view/67039?key=3afdba3bdd597a169a37
TITLE:
Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance
AUTHOR CONTACT:
Amer Beg
LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, Tampa, FL, USA
Phone: 813-745-5714; E-mail: amer.beg@moffitt.org
View this article at: http://www.jci.org/articles/view/67250?key=ec2f042511c98c04245d
Journal
Journal of Clinical Investigation